Oncology

Second-line treatment with trastuzumab deruxtecan has been shown to extend overall survival by more than 3 months in patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma (GEJA) following progression on first-line therapy, according to Phase III data from the DESTINY-Gastric04 trial presented at the ASCO 2025 Annual Meeting.

First-line maintenance treatment with lurbinectedin and atezolizumab significantly improves survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC), according to primary results from the global Phase III IMforte trial presented at ASCO 2025.

A NEW oral therapy may significantly delay disease progression in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, according to results presented at the 2025 ASCO Annual Meeting.

A novel artificial intelligence (AI) framework called AutoRadAI has demonstrated strong diagnostic performance in detecting extracapsular extension (ECE) in prostate cancer, a key prognostic factor that can significantly impact treatment planning and surgical outcomes.

In the high-stakes landscape of cancer treatment where healthcare professionals rely on cost-effectiveness analyses to guide decisions adverse event costs may be throwing off the equation.

A new study sheds light on the hidden cardiovascular risks lurking in the critical first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT).

Prostate cancer survivors face a long-term threat that often goes undetected, a third primary cancer, according to new findings that highlight an under-recognized but serious risk with significant survival implications.

A new national study published ahead of print in JCO Oncology Practice reveals a steady increase in time to treatment initiation (TTI) across all 30 of the most prevalent cancer types, with early-stage diagnoses now a major driver of these delays.